GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cell Culture
2.2. RNA-Seq Sample Preparation
2.3. RNA-Seq Data Processing
2.4. Flow Cytometry
2.5. Immunofluroescence Microscopy
2.6. Tumor Tissue Acquisition and PDX Passaging
2.7. Image Analysis
3. Results
3.1. GLUT3 Is Highly Expressed in Hypoxic Immortalized Prostate Epithelial Cells
3.2. GLUT3 Protein Levels Are Elevated in Hypoxic Prostate Epithelial Cells and Prostate Cancer Cells
3.3. GLUT3 Colocalizes with Pimonidazole-Labeled Regions of Hypoxia in Mouse Xenograft Tumors
3.4. A Combination of Biomarker Stains Provides the Best Coverage of Hypoxic Regions in Patient-Derived Xenograft (PDX) Models of Prostate Cancer
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Harris, A.L. Hypoxia—A key regulatory factor in tumour growth. Nat. Cancer 2002, 2, 38–47. [Google Scholar] [CrossRef] [PubMed]
- Nussenbaum, F.; Herman, I.M. Tumor Angiogenesis: Insights and Innovations. J. Oncol. 2010, 2010, 132641. [Google Scholar] [CrossRef] [Green Version]
- McKeown, S.R. Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response. Br. J. Radiol. 2014, 87, 20130676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bader, S.B.; Dewhirst, M.W.; Hammond, E.M. Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer. Cancers 2020, 13, 23. [Google Scholar] [CrossRef] [PubMed]
- Vaupel, P.; Mayer, A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26, 225–239. [Google Scholar] [CrossRef]
- Ruan, K.; Song, G.; Ouyang, G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009, 107, 1053–1062. [Google Scholar] [CrossRef]
- Graeber, T.; Osmanian, C.; Jacks, T.; Housman, D.E.; Koch, C.J.; Lowe, S.W.; Giaccia, A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379, 88–91. [Google Scholar] [CrossRef]
- Vaupel, P. Metabolic microenvironment of tumor cells: A key factor in malignant progression. Exp. Oncol. 2010, 32, 125–127. [Google Scholar]
- Jiang, J.; Tang, Y.-L.; Liang, X.-H. EMT: A new vision of hypoxia promoting cancer progression. Cancer Biol. Ther. 2011, 11, 714–723. [Google Scholar] [CrossRef] [Green Version]
- Bristow, R.G.; Hill, R.P. Hypoxia, DNA repair and genetic instability. Nat. Cancer 2008, 8, 180–192. [Google Scholar] [CrossRef]
- Semenza, G.L. Hypoxia-Inducible Factors in Physiology and Medicine. Cell 2012, 148, 399–408. [Google Scholar] [CrossRef] [Green Version]
- Rankin, E.B.; Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15, 678–685. [Google Scholar] [CrossRef] [Green Version]
- Liao, D.; Johnson, R.S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26, 281–290. [Google Scholar] [CrossRef]
- De Bock, K.; Mazzone, M.; Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: Risky liaisons, or not? Nat. Rev. Clin. Oncol. 2011, 8, 393–404. [Google Scholar] [CrossRef] [Green Version]
- Semenza, G.L. The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim. Biophys. Acta 2015, 1863, 382–391. [Google Scholar] [CrossRef]
- Rankin, E.B.; Giaccia, A.J. Hypoxic control of metastasis. Science 2016, 352, 175–180. [Google Scholar] [CrossRef] [Green Version]
- Multhoff, G.; Vaupel, P. Hypoxia Compromises Anti-Cancer Immune Responses. Oxyg. Transp. Tissue XLI 2020, 1232, 131–143. [Google Scholar] [CrossRef]
- Höckel, M.; Schlenger, K.; Höckel, S.; Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59, 4525–4528. [Google Scholar]
- Höckel, M.; Vaupel, P. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects. JNCI J. Natl. Cancer Inst. 2001, 93, 266–276. [Google Scholar] [CrossRef] [Green Version]
- Schindl, M.; Schoppmann, S.F.; Samonigg, H.; Hausmaninger, H.; Kwasny, W.; Gnant, M.; Jakesz, R.; Kubista, E.; Birner, P.; Oberhuber, G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 2002, 8, 1831–1837. [Google Scholar]
- Yamamoto, Y.; Ibusuki, M.; Okumura, Y.; Kawasoe, T.; Kai, K.; Iyama, K.; Iwase, H. Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res. Treat. 2007, 110, 465–475. [Google Scholar] [CrossRef] [PubMed]
- Chandel, N.S.; Maltepe, E.; Goldwasser, E.; Mathieu, C.E.; Simon, M.C.; Schumacker, P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 1998, 95, 11715–11720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dang, C.V.; Semenza, G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999, 24, 68–72. [Google Scholar] [CrossRef]
- Warburg, O. On the Origin of Cancer Cells. Science 1956, 123, 309–314. [Google Scholar] [CrossRef] [PubMed]
- Wykoff, C.C.; Beasley, N.J.; Watson, P.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.; Turley, H.; Talks, K.L.; Maxwell, P.; et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075–7083. [Google Scholar] [PubMed]
- Ivanov, S.; Liao, S.-Y.; Ivanova, A.; Danilkovitch-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M.J.; Proescholdt, M.A.; Oldfield, E.H.; Lee, J.; et al. Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer. Am. J. Pathol. 2001, 158, 905–919. [Google Scholar] [CrossRef] [Green Version]
- Sowter, H.M.; Raval, R.R.; Moore, J.W.; Ratcliffe, P.J.; Harris, A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003, 63, 6130–6134. [Google Scholar] [PubMed]
- Loncaster, J.A.; Harris, A.; Davidson, S.E.; Logue, J.P.; Hunter, R.D.; Wycoff, C.C.; Pastorek, J.; Ratcliffe, P.; Stratford, I.J.; West, C. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61, 6394–6399. [Google Scholar] [PubMed]
- Wykoff, C.C.; Beasley, N.; Watson, P.H.; Campo, L.; Chia, S.K.; English, R.; Pastorek, J.; Sly, W.S.; Ratcliffe, P.; Harris, A. Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast. Am. J. Pathol. 2001, 158, 1011–1019. [Google Scholar] [CrossRef] [Green Version]
- Saarnio, J.; Parkkila, S.; Parkkila, A.-K.; Waheed, A.; Casey, M.C.; Zhou, X.Y.; Pastoreková, S.; Pastorek, J.; Karttunen, T.; Haukipuro, K.; et al. Immunohistochemistry of Carbonic Anhydrase Isozyme IX (MN/CA IX) in Human Gut Reveals Polarized Expression in the Epithelial Cells with the Highest Proliferative Capacity. J. Histochem. Cytochem. 1998, 46, 497–504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chia, S.K.; Wykoff, C.C.; Watson, P.; Han, C.; Leek, R.D.; Pastorek, J.; Gatter, K.C.; Ratcliffe, P.; Harris, A. Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma. J. Clin. Oncol. 2001, 19, 3660–3668. [Google Scholar] [CrossRef] [PubMed]
- Hussain, S.A.; Ganesan, R.; Reynolds, G.; Gross, L.; Stevens, A.; Pastorek, J.; Murray, P.G.; Perunovic, B.; Anwar, M.S.; Billingham, L.; et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 2007, 96, 104–109. [Google Scholar] [CrossRef]
- Ord, J.J.; Agrawal, S.; Thamboo, T.P.; Roberts, I.; Campo, L.; Turley, H.; Han, C.; Fawcett, D.W.; Kulkarni, R.P.; Cranston, D.; et al. An Investigation Into the Prognostic Significance of Necrosis and Hypoxia in High Grade and Invasive Bladder Cancer. J. Urol. 2007, 178, 677–682. [Google Scholar] [CrossRef]
- Swinson, D.E.; Jones, J.L.; Richardson, D.; Wykoff, C.; Turley, H.; Pastorek, J.; Taub, N.; Harris, A.; O’Byrne, K.J. Carbonic Anhydrase IX Expression, a Novel Surrogate Marker of Tumor Hypoxia, Is Associated With a Poor Prognosis in Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2003, 21, 473–482. [Google Scholar] [CrossRef]
- Trastour, C.; Benizri, E.; Ettore, F.; Ramaioli, A.; Chamorey, E.; Pouysségur, J.; Berra, E. HIF-1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int. J. Cancer 2007, 120, 1451–1458. [Google Scholar] [CrossRef]
- Okino, S.T.; Chichester, C.H.; Whitlock, J.P. Hypoxia-inducible Mammalian Gene Expression Analyzed in Vivo at a TATA-driven Promoter and at an Initiator-driven Promoter. J. Biol. Chem. 1998, 273, 23837–23843. [Google Scholar] [CrossRef] [Green Version]
- Zelzer, E.; Levy, Y.; Kahana, C.; Shilo, B.; Rubinstein, M.; Cohen, B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha /ARNT. EMBO J. 1998, 17, 5085–5094. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.; Pore, N.; Behrooz, A.; Ismail-Beigi, F.; Maity, A. Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. J. Biol. Chem. 2001, 276, 9519–9525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Macheda, M.L.; Rogers, S.; Best, J. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2004, 202, 654–662. [Google Scholar] [CrossRef] [PubMed]
- Pessin, J.E.; Bell, G.I. Mammalian Facilitative Glucose Transporter Family: Structure and Molecular Regulation. Annu. Rev. Physiol. 1992, 54, 911–930. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.-Z.; Behrooz, A.; Ismail-Beigi, F. Regulation of glucose transport by hypoxia. Am. J. Kidney Dis. 1999, 34, 189–202. [Google Scholar] [CrossRef]
- Trédan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug Resistance and the Solid Tumor Microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441–1454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Butterworth, K.T.; McCarthy, H.O.; Devlin, A.; Ming, L.; Robson, T.; McKeown, S.R.; Worthington, J. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int. J. Cancer 2008, 123, 760–768. [Google Scholar] [CrossRef] [PubMed]
- Milosevic, M.; Warde, P.; Menard, C.; Chung, P.; Toi, A.; Ishkanian, A.; McLean, M.; Pintilie, M.; Sykes, J.; Gospodarowicz, M.; et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin. Cancer Res. 2012, 18, 2108–2114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ashton, J.; Bristow, R. Bad neighbours: Hypoxia and genomic instability in prostate cancer. Br. J. Radiol. 2020, 93, 20200087. [Google Scholar] [CrossRef] [PubMed]
- Thiry, A.; Dogné, J.-M.; Masereel, B.; Supuran, C.T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 2006, 27, 566–573. [Google Scholar] [CrossRef] [PubMed]
- Stewart, G.D.; Gray, K.; Pennington, C.J.; Edwards, D.R.; Riddick, A.C.; Ross, J.A.; Habib, F.K. Analysis of hypoxia-associated gene expression in prostate cancer: Lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol. Rep. 1994, 20, 1561–1567. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Wang, H.; Oosterwijk, E.; Selman, Y.; Mira, J.C.; Medrano, T.; Shiverick, K.T.; Frost, S.C. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem. Biophys. Res. Commun. 2009, 386, 488–492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Donato, D.P.; Johnson, M.T.; Yang, X.J.; Zynger, D.L. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology 2011, 59, 1229–1239. [Google Scholar] [CrossRef] [PubMed]
- Chandler, J.D.; Williams, E.; Slavin, J.L.; Best, J.D.; Rogers, S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 2003, 97, 2035–2042. [Google Scholar] [CrossRef] [PubMed]
- Fraga, A.; Ribeiro, R.; Príncipe, P.; Lopes, C.; Medeiros, R. Hypoxia and prostate cancer aggressiveness: A tale with many endings. Clin. Genitourin. Cancer 2015, 13, 295–301. [Google Scholar] [CrossRef] [PubMed]
- Wang, M.; Knudsen, B.S.; Nagle, R.B.; Rogers, G.C.; Cress, A.E. A method of quantifying centrosomes at the single-cell level in human normal and cancer tissue. Mol. Biol. Cell 2019, 30, 811–819. [Google Scholar] [CrossRef] [PubMed]
- Tommasi, S.; Pilato, B.; Carella, C.; Lasorella, A.; Danza, K.; Vallini, I.; De Summa, S.; Naglieri, E. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. Prostate 2018, 79, 54–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denko, N.C.; Fontana, L.A.; Hudson, K.M.; Sutphin, P.D.; Raychaudhuri, S.; Altman, R.; Giaccia, A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22, 5907–5914. [Google Scholar] [CrossRef] [Green Version]
- Zhong, H.; Semenza, G.L.; Simons, J.W.; De Marzo, A.M. Up-regulation of hypoxia-inducible factor 1α is an early event in prostate carcinogenesis. Cancer Detect. Prev. 2004, 28, 88–93. [Google Scholar] [CrossRef]
- Deep, G.; Panigrahi, G.K. Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment. Crit. Rev. Oncog. 2015, 20, 419–434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bello, D.; Webber, M.M.; Kleinman, H.K.; Wartinger, D.D.; Rhim, J.S. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997, 18, 1215–1223. [Google Scholar] [CrossRef]
- Corn, P.G.; Ricci, M.S.; Scata, K.A.; Arsham, A.M.; Simon, M.C.; Dicker, D.T.; El-Deiry, W.S. Mxi1 is induced by hypoxia in a HIF-1–dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol. Ther. 2005, 4, 1285–1294. [Google Scholar] [CrossRef] [Green Version]
- To, K.; Sedelnikova, O.A.; Samons, M.; Bonner, W.M.; Huang, L.E. The phosphorylation status of PAS-B distinguishes HIF-1α from HIF-2α in NBS1 repression. EMBO J. 2006, 25, 4784–4794. [Google Scholar] [CrossRef] [Green Version]
- Hammer, S.; To, K.; Yoo, Y.-G.; Koshiji, M.; Huang, L.E. Hypoxic Suppression of the Cell Cycle GeneCDC25Ain Tumor Cells. Cell Cycle 2007, 6, 1919–1926. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, L.E. Carrot and stick: HIF-α engages c-Myc in hypoxic adaptation. Cell Death Differ. 2008, 15, 672–677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Y.; Sun, X.-X.; Qian, D.Z.; Dai, M.-S. Molecular Crosstalk Between MYC and HIF in Cancer. Front. Cell Dev. Biol. 2020, 8, 1319. [Google Scholar] [CrossRef] [PubMed]
- Kind, K.L.; Collett, R.A.; Harvey, A.J.; Thompson, J.G. Oxygen-regulated expression ofGLUT-1,GLUT-3, andVEGF in the mouse blastocyst. Mol. Reprod. Dev. 2004, 70, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Baumann, M.U.; Zamudio, S.; Illsley, N. Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1. Am. J. Physiol. Physiol. 2007, 293, C477–C485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fung, C.; Evans, E.; Shin, D.; Shin, B.-C.; Zhao, Y.; Sankar, R.; Chaudhuri, G.; Devaskar, S.U. Hypoxic-ischemic brain injury exacerbates neuronal apoptosis and precipitates spontaneous seizures in glucose transporter isoform 3 heterozygous null mice. J. Neurosci. Res. 2010, 88, 3386–3398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sweet, R.; Paul, A.; Zastre, J. Hypoxia induced upregulation and function of the thiamine transporter, SLC19A3 in a breast cancer cell line. Cancer Biol. Ther. 2010, 10, 1101–1111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Christensen, D.; Calder, P.; Houghton, F.D. GLUT3 and PKM2 regulate OCT4 expression and support the hypoxic culture of human embryonic stem cells. Sci. Rep. 2015, 5, 17500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luo, W.; Chen, I.; Chen, Y.; Alkam, D.; Wang, Y.; Semenza, G.L. PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia. Oncotarget 2016, 7, 6379–6397. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baudel, M.A.S.M.-A.; Rae, M.T.; Darlison, M.G.; Poole, A.V.; Fraser, J.A. Preferential activation of HIF-2α adaptive signalling in neuronal-like cells in response to acute hypoxia. PLoS ONE 2017, 12, e0185664. [Google Scholar] [CrossRef] [Green Version]
- Yang, L.; Roberts, D.; Takhar, M.; Erho, N.; Bibby, B.A.; Thiruthaneeswaran, N.; Bhandari, V.; Cheng, W.-C.; Haider, S.; McCorry, A.; et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine 2018, 31, 182–189. [Google Scholar] [CrossRef] [Green Version]
- Wu, X.; Freeze, H.H. GLUT14, a Duplicon of GLUT3, Is Specifically Expressed in Testis as Alternative Splice Forms. Genomics 2002, 80, 553–557. [Google Scholar] [CrossRef] [PubMed]
- Varia, M.A.; Calkins-Adams, D.P.; Rinker, L.H.; Kennedy, A.S.; Novotny, D.B.; Fowler, W.C.; Raleigh, J.A. Pimonidazole: A Novel Hypoxia Marker for Complementary Study of Tumor Hypoxia and Cell Proliferation in Cervical Carcinoma. Gynecol. Oncol. 1998, 71, 270–277. [Google Scholar] [CrossRef] [PubMed]
- Kleiter, M.M.; Thrall, D.E.; Malarkey, D.E.; Ji, X.; Lee, D.Y.; Chou, S.-C.; Raleigh, J.A. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int. J. Radiat. Oncol. 2006, 64, 592–602. [Google Scholar] [CrossRef] [PubMed]
- Ragnum, H.B.; Vlatkovic, L.; Lie, A.K.; Axcrona, K.; Julin, C.H.; Frikstad, K.-A.M.; Hole, K.H.; Seierstad, T.; Lyng, H. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br. J. Cancer 2014, 112, 382–390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turaka, A.; Buyyounouski, M.K.; Hanlon, A.L.; Horwitz, E.M.; Greenberg, R.E.; Movsas, B. Hypoxic Prostate/Muscle Po2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. Int. J. Radiat. Oncol. 2012, 82, e433–e439. [Google Scholar] [CrossRef] [PubMed]
- Lalonde, E.; Ishkanian, A.S.; Sykes, J.; Fraser, M.; Ross-Adams, H.; Erho, N.; Dunning, M.; Halim, S.; Lamb, A.D.; Moon, N.C.; et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study. Lancet Oncol. 2014, 15, 1521–1532. [Google Scholar] [CrossRef]
- Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Tissue-Based Map of the Human Proteome. Science 2015, 347, 1260419. [Google Scholar] [CrossRef]
- Uhlén, M.; Zhang, C.; Lee, S.; Sjöstedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.; et al. A pathology atlas of the human cancer transcriptome. Science 2017, 357, 2507. [Google Scholar] [CrossRef] [Green Version]
- Simpson, I.A.; Dwyer, D.; Malide, D.; Moley, K.H.; Travis, A.; Vannucci, S.J. The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol. Metab. 2008, 295, E242–E253. [Google Scholar] [CrossRef] [Green Version]
- Custódio, T.F.; Paulsen, P.A.; Frain, K.M.; Pedersen, B.P. Structural comparison of GLUT1 to GLUT3 reveal transport regulation mechanism in sugar porter family. Life Sci. Alliance 2021, 4, e202000858. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ryniawec, J.M.; Coope, M.R.; Loertscher, E.; Bageerathan, V.; de Oliveira Pessoa, D.; Warfel, N.A.; Cress, A.E.; Padi, M.; Rogers, G.C. GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics 2022, 12, 676. https://doi.org/10.3390/diagnostics12030676
Ryniawec JM, Coope MR, Loertscher E, Bageerathan V, de Oliveira Pessoa D, Warfel NA, Cress AE, Padi M, Rogers GC. GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics. 2022; 12(3):676. https://doi.org/10.3390/diagnostics12030676
Chicago/Turabian StyleRyniawec, John M., Matthew R. Coope, Emily Loertscher, Vignesh Bageerathan, Diogo de Oliveira Pessoa, Noel A. Warfel, Anne E. Cress, Megha Padi, and Gregory C. Rogers. 2022. "GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors" Diagnostics 12, no. 3: 676. https://doi.org/10.3390/diagnostics12030676
APA StyleRyniawec, J. M., Coope, M. R., Loertscher, E., Bageerathan, V., de Oliveira Pessoa, D., Warfel, N. A., Cress, A. E., Padi, M., & Rogers, G. C. (2022). GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors. Diagnostics, 12(3), 676. https://doi.org/10.3390/diagnostics12030676